Open label, healthy volunteers, ADME study with single oral administration of [14C] AZD5069
Study identifier:D3550C00013
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Phase I, Open-Label Study to Characterise the Absorption, Distribution, Metabolism and Excretion following a Single Oral Dose of [14C]AZD5069 in Healthy Male Volunteers
Medical condition
Healthy
Phase
Phase 1
Healthy volunteers
Yes
Study drug
[14C] AZD5069
Sex
Male
Actual Enrollment
6
Study type
Interventional
Age
50 Years +
Date
Study Start Date: 01 May 2011
Primary Completion Date: 01 Jul 2011
Study Completion Date: 01 Jul 2011
Study design
Allocation: N/A
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Basic Science
Verification:
Verified 01 Jun 2015 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 [14C] AZD5069 | Drug: [14C] AZD5069 Single 120 mg oral dose administered on Day 1 |
Contacts
Investigators
Principal Investigator
Prof. Tim Mant
Quintiles Drug Research Unit at Guy's Hospital
